20 Years of Priority Review Vouchers, a Tool for Spurring Needed Drugs
TL;DR AI
2 min readKey summary
The priority review voucher idea, first proposed 20 years ago, is back in focus.
A 2007 U.S. law gives FDA review-acceleration vouchers to companies that win approval for neglected tropical disease drugs.
The policy helps make treatments for commercially unattractive diseases more worthwhile to develop.
It is a rare tool that shifts pharmaceutical incentives toward diseases that disproportionately affect low- and middle-income countries.
Same topic
